Pharma BD Deal Intelligence
Wyeth brought Prevnar, biologics platform, and $4B synergies but stock underperformed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer Inc., announced Monday it is acquiring rival company Wyeth for about $68 billion, in the largest pharmaceutical sector takeover since 2000.
Pfizer Inc today announced the completion of its acquisition of Wyeth, creating the world's premier biopharmaceutical company.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer acquired Wyeth for approximately $68 billion in a cash-and-stock transaction, gaining a leading biologics portfolio including Prevnar and Enbrel, diversifying beyond small molecules into vaccines, biologics, and consumer health.
Wyeth brought Prevnar, biologics platform, and $4B synergies but stock underperformed
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Wyeth (this deal) | 2009 | $68.0B | 86 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2009 deals · Pfizer Inc. deals · Cardiovascular deals